Can we afford to develop treatments for dementia?

Journal of Neurology Neurosurgery and Psychiatry

Volumn 72, Issue 6, 2002, Pages 685-

  Lovestone, S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR;

ALZHEIMER DISEASE; DEMENTIA; EDITORIAL; EXPERIENCE; HUMAN; NERVE DEGENERATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

CLINICAL TRIALS; COST OF ILLNESS; DEMENTIA; EVIDENCE-BASED MEDICINE; HUMANS; RESEARCH SUPPORT;

EID: 0036266107     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.72.6.685     Document Type: Editorial

References (13)

1. Present and future of Alzheimer therapy
2. The genetics and molecular pathology of Alzheimer's disease: Roles of amyloid and the presenilins
3. β-amyloid (Aβ)42(43), Aβ42, Aβ40 and apoE immunostaining of plaques in fatal head injury
4. β amyloid protein deposition in the brain after severe head injury: Implications for the pathogenesis of Alzheimer's disease
5. Linkage of Plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees
6. Alzheimer's disease: Do fauists and baptists finally shake hands?
7. Activation of tau protein kinase I/glycogen synthase kinase-3β by amyloid β peptide (25-35) enhances phosphorylation of tau in hippocampal neurons
8. Lithium protects cultured neurons against β-amyloid-induced neurodegeneration
9. Untangling tau-related dementia
10. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales
11. Neuropathology of synuclein aggregates
12. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease
13. Mild cognitive impairment represents early-stage Alzheimer disease